Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 10/20 | 0.41 |
| ▸ | NPY1R | P25929 | 7/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.41 |
| ▸ | NPY2R | P49146 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 6/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TFPI | P10646 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632351 | 1.00 | KEAP1 (0.42) | KEAP1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL10074918 | 0.91 | NPY4R (0.55) | KEAP1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL2632420 | 0.88 | KEAP1 (0.42) | KEAP1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL10074914 | 0.87 | NPY4R (0.55) | KEAP1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL2632331 | 0.87 | NPY4R (0.51) | KEAP1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL2632215 | 0.85 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL2632397 | 0.85 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL13188101 | 0.84 | KEAP1 (0.36) | KEAP1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13187702 | 0.84 | KEAP1 (0.36) | KEAP1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13188059 | 0.83 | NPY4R (0.52) | KEAP1NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | UNIVERSITE DE MONTREAL (CA) | 2012-04-26 | — | — | US | disclosed |
| WO-2010106441-A2 | PEPTIDOMIMETICS FOR MODULATING INTERLEUKIN-1 RECEPTOR | CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE (CA) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | QPCT, GLUL, ASNS | KEAP1 4065/4885NPY4R 2134/4885NPY1R 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.